HRs for calcium plus vitamin D are also repeated from earlier tables for comparative purposes. As mentioned previously, these HRs are subject to residual confounding and other biases, but comparative HRs across supplement types presumably less so. Significant associations were not found for hip fracture or for total fracture for either supplement alone or combined. No associations of check details calcium or vitamin

D with incidence for the specific cancer sites considered or for total invasive cancer were suggested by these Table 5 analyses. A non-significant early elevation in MI incidence with vitamin D is not precisely estimated and is not BAY 11-7082 mw apparent with the combination of calcium and vitamin D. HR estimates were below one (P < 0.05) for calcium alone in relation to MI and CHD, and as previously mentioned, for CaD in relation to total heart disease. Table 5 Hazard ratios and 95 % confidence intervals for supplementation of calcium only and vitamin D only and for calcium and vitamin D combined from the

WHI Observational Study, according to years from supplement initiation Years from Supplement Initiation Calcium only Vitamin D only CaD Calcium only Vitamin D only CaD HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI   Hip fracture Total fracture <2 2.85 0.67,12.12 2.51 0.34,18.60 1.41 0.44,4.57 0.69 0.37,1.29 1.53 0.82,2.86 0.89 0.61,1.31 2–5 0.60 0.19,1.89 1.44 0.45,4.56 1.22 0.71,2.10 0.93 0.75,1.16 Combretastatin A4 in vivo 1.19 0.88,1.61 1.05 0.91,1.22 >5 0.82 0.58,1.15 1.17 0.73,1.86 0.84 0.66,1.07 1.00 0.91,1.09 1.02 0.88,1.18 1.08 1.01,1.14 Trend testa 0.49   0.48   0.14   0.26   0.15   0.42   Overall HRb 0.82 0.59, 1.14 1.23 0.80, 1.88 0.88 0.70,1.11 0.99 0.91,1.07 1.06 0.93,1.20 1.07 1.01,1.14   Myocardial infarction Coronary heart disease <2 0.85 0.21,3.48 1.72 0.42,7.06 0.56 0.14,2.27 0.77 0.19,3.13 1.59 0.39,6.48 0.49 0.12,2.00 2–5 0.87 0.44,1.69 1.28 0.57,2.89 1.04 0.66,1.63 0.96 0.54,1.72 1.07 0.48,2.41 1.00 0.66,1.53 >5 0.71 0.53,0.97 0.99 0.67,1.47 0.89 0.73,1.08 0.74 0.56,0.97 1.02 0.72,1.45

0.88 0.74,1.05 Trend testa 0.60   0.38   0.94   0.53   0.61   0.88   Overall HRb 0.74 0.56, 0.97 1.06 0.75, 1.51 0.90 0.75,1.09 0.74 0.58,0.95 1.04 0.76,1.43 0.88 0.74,1.04   Total heart disease Mirabegron Stroke <2 1.07 0.57,2.00 1.32 0.59,2.96 0.86 0.50,1.46 0.84 0.21,3.41 NAc 0.47 0.12,1.89 2–5 1.05 0.78,1.42 0.83 0.51,1.36 0.93 0.73,1.17 1.04 0.58,1.86 0.77 0.29,2.07 0.91 0.57,1.44 >5 0.95 0.82,1.10 0.97 0.78,1.20 0.87 0.79,0.97 0.81 0.62,1.07 0.82 0.55,1.23 0.93 0.77,1.11 Trend testa 0.47   0.82   0.83   0.47   0.45   0.28   Overall HRb 0.95 0.83, 1.08 0.96 0.79, 1.16 0.87 0.79,0.96 0.84 0.66,1.07 0.80 0.55,1.15 0.92 0.77,1.09   TOTAL CARDIOVASCULAR DISEASE COLORECTAL CANCER <2 0.99 0.57,1.72 1.09 0.52,2.30 0.87 0.55,1.35 1.03 0.14,7.47 NAc 0.94 0.23,3.87 2–5 1.02 0.78,1.32 0.90 0.60,1.34 0.91 0.74,1.11 1.05 0.42,2.58 0.95 0.23,3.88 0.80 0.39,1.65 >5 0.89 0.79,1.01 0.92 0.76,1.10 0.86 0.79,0.94 1.01 0.66,1.55 0.64 0.28,1.46 0.83 0.60,1.14 Trend testa 0.